Your browser doesn't support javascript.
loading
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo, Courtney D; Venugopal, Sangeetha; Lachowiez, Curtis; Takahashi, Koichi; Loghavi, Sanam; Montalban-Bravo, Guillermo; Wang, Xuemei; Carraway, Hetty; Sekeres, Mikkael; Sukkur, Ameenah; Hammond, Danielle; Chien, Kelly; Maiti, Abhishek; Masarova, Lucia; Sasaki, Koji; Alvarado, Yesid; Kadia, Tapan; Short, Nicholas J; Daver, Naval; Borthakur, Gautam; Ravandi, Farhad; Kantarjian, Hagop M; Patel, Bhumika; Dezern, Amy; Roboz, Gail; Garcia-Manero, Guillermo.
Affiliation
  • DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Venugopal S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lachowiez C; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Takahashi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Montalban-Bravo G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Carraway H; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Sekeres M; Division of Hematology, Sylvester Cancer Center, University of Miami, Miami, FL.
  • Sukkur A; Weill Cornell Medical College, The New York Presbyterian Hospital, New York, NY.
  • Hammond D; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chien K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Maiti A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Masarova L; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sasaki K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kadia T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Short NJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Patel B; Leukemia Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Dezern A; Division of Hematologic Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
  • Roboz G; Weill Cornell Medical College, The New York Presbyterian Hospital, New York, NY.
  • Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv ; 7(11): 2378-2387, 2023 06 13.
Article in En | MEDLINE | ID: mdl-35973199
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Isocitrate Dehydrogenase Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Blood Adv Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Isocitrate Dehydrogenase Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Humans Language: En Journal: Blood Adv Year: 2023 Document type: Article